Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The antibiotics market

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Antibiotics sales by class in 2009 in US$ billions.
Figure 2: Current status of antibiotic R&D activity at each development stage.


  1. IMS Health. IMS MIDAS (2009).

  2. Rice, L. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197, 1079–1081 (2008).

    Article  PubMed  Google Scholar 

  3. Projan, S. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427–430 (2003).

    Article  PubMed  Google Scholar 

  4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: non-inferiority clinical trials. FDA website [online], (2010).

  5. Extance, A. Biologics target bad bugs. Nature Rev. Drug Discov. 9, 177–178 (2010).

    CAS  Article  Google Scholar 

  6. IMS Health. IMS LifeCycle (2009).

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hamad, B. The antibiotics market. Nat Rev Drug Discov 9, 675–676 (2010).

Download citation

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing